Cost-effectiveness of fractional exhaled nitric oxide (FeNO) measurement in predicting response to omalizumab in asthma

Purpose: To use a modeled analysis to examine the cost-effectiveness of utilizing fractional exhaled nitric oxide (FeNO) as a biomarker to aid in the identification of omalizumab responders in patients with moderate-to-severe allergic asthma. Omalizumab is a biological drug used to treat asthma in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Brooks, Elizabeth A, Massanari, Marc, Hanania, Nicola A, Weiner, Daniel J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497051/
https://www.ncbi.nlm.nih.gov/pubmed/31114270
http://dx.doi.org/10.2147/CEOR.S177207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497051/
https://www.ncbi.nlm.nih.gov/pubmed/31114270
http://dx.doi.org/10.2147/CEOR.S177207

Ejemplares similares